Clinical Trials · NCT01452451
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Enrollment
- 72
- Start date
- Dec 2011
- Locations
- 1 site, United States
- Primary endpoint
- Number of subjects with adverse events as a measure of safety and tolerability